{
    "clinical_study": {
        "@rank": "30092", 
        "brief_summary": {
            "textblock": "Extent of use of generics immunosuppressive drugs in clinical practice after lung\n      transplantation"
        }, 
        "brief_title": "Generic Immunosuppressive Drugs After Lung Transplantation", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Immunosuppressive After Lung Transplantation", 
        "detailed_description": {
            "textblock": "Solid organ transplant recipients are treated with immunosuppressive drugs to prevent\n      rejection of their grafts. The most frequently important maintenance immunosuppressive drugs\n      in Europe are calcineurin inhibitors.\n\n      For a number of these compounds drug patents have expired in recent years and generic\n      formulations have entered the market. There is considerable debate regarding the efficacy\n      and safety of generic drug substitution in solid organ recipients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients after lung transplantation (single, double or combined)\n\n          -  informed consent\n\n          -  patient with an immunosuppressive therapy with tacrolimus or ciclosporin\n\n        Exclusion Criteria:\n\n          -  immunosuppressive therapy without calcineurin inhibitors\n\n          -  need for isolation (Colonization with multi. or pan resistant organisms e.g.\n             methicillin-resistant staph. aureus[MRSA), B. cenocepacia)\n\n          -  limited German language skills or other reasons which might impair patient\n             communication or computer handling"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "patients after lung transplantation (single, double or combined) with an immunosuppressive\n        therapy with tacrolimus or ciclosporin"
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01889017", 
            "org_study_id": "V 1.0 22/05/2013"
        }, 
        "intervention": {
            "intervention_name": "patient questionnaire (tablet pc based)", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Immunosuppressive Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "generic immunosuppressive", 
        "lastchanged_date": "July 15, 2013", 
        "location": {
            "contact": {
                "last_name": "Imke Zinowsky", 
                "phone": "0049-5115325841"
            }, 
            "facility": {
                "address": {
                    "city": "Hanover", 
                    "country": "Germany", 
                    "state": "Lower Saxony", 
                    "zip": "30625"
                }, 
                "name": "Hannover Medical School"
            }, 
            "investigator": [
                {
                    "last_name": "Jens Gottlieb, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Mark Greer, MB", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Felix Ringshausen, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Generic Immunosuppressive Drugs After Lung Transplantation - a Crosssectional Observational Study by Patient Questionnaire", 
        "overall_contact": {
            "email": "gottlieb.jens@mh-hannover.de", 
            "last_name": "Jens Gottlieb, MD", 
            "phone": "0049511-532", 
            "phone_ext": "4601"
        }, 
        "overall_contact_backup": {
            "email": "zinowsky.imke@mh-hannover.de", 
            "last_name": "Imke Zinowsky", 
            "phone": "0049511-532", 
            "phone_ext": "5841"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Frequency of use of generic immunosuppressive drugs", 
            "safety_issue": "No", 
            "time_frame": "baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01889017"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hannover Medical School", 
            "investigator_full_name": "Thomas Fuehner", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Frequency of calcineurin inhibitor through levels in target range between generic and original immunosuppressive drugs during last 6 months", 
                "measure": "Calcineurin inhibitor through levels", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, retrospective 6 months"
            }, 
            {
                "description": "Dose of calcineurin inhibitors between generic and original immunosuppressive drugs at questionnaire", 
                "measure": "Dose of calcineurin inhibitors", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "Therapy adherence between generic and original immunosuppressive drugs. Adherence will be measured by a 5 item Likert scale covering self-monitoring, generla health perception, contacts, nutrition/exercise compliance and adherence to immunosuppression.", 
                "measure": "Therapy adherence", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "Satisfaction with immunosuppression between generic and original immunosuppressive drugs will be measured by a 5-point Likert scale.", 
                "measure": "Satisfaction with immunosuppression", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }
        ], 
        "source": "Hannover Medical School", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hannover Medical School", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "June 2013"
    }
}